Chiang Jeremy Chung Bo, Zahari Ilyanoon, Markoulli Maria, Krishnan Arun V, Park Susanna B, Semmler Annalese, Goldstein David, Edwards Katie
School of Optometry & Vision Science, University of New South Wales, Sydney, Australia.
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia; Department of Optometry & Visual Science, International Islamic University Malaysia, Kuantan, Malaysia.
Ocul Surf. 2020 Jul;18(3):403-417. doi: 10.1016/j.jtos.2020.03.008. Epub 2020 Apr 25.
Cancer is a global health problem and is one of the leading causes of death worldwide. Pleasingly, the rate of survival has improved and continues in an upward trend mainly due to better diagnosis and treatment modalities. In particular, the development of anticancer drugs including cytotoxic chemotherapy, hormonal agents and targeted therapies have provided the most effective treatment options in combatting cancerous cells. However, the antineoplastic mechanisms of these drugs can also lead to undesirable systemic and ocular side effects resulting from cytotoxicity, inflammation and neurotoxicity. While survival rates are projected to increase with time, the number of patients presenting with these side effects that can substantially impact quality of life will also rise. The current paper reviews the ocular surface and adnexal side effects of anticancer drugs, the appropriate management and possible interactions between drugs for ocular surface pathology treatment and the anticancer drugs.
癌症是一个全球性的健康问题，也是全球主要的死亡原因之一。令人欣慰的是，生存率有所提高且呈持续上升趋势，这主要归功于更好的诊断和治疗方式。特别是，包括细胞毒性化疗、激素药物和靶向治疗在内的抗癌药物的发展，为对抗癌细胞提供了最有效的治疗选择。然而，这些药物的抗肿瘤机制也可能导致由细胞毒性、炎症和神经毒性引起的不良全身和眼部副作用。虽然预计生存率会随着时间的推移而提高，但出现这些会严重影响生活质量的副作用的患者数量也会增加。本文综述了抗癌药物的眼表和附件副作用、适当的管理方法，以及用于眼表疾病治疗的药物与抗癌药物之间可能的相互作用。
